News | August 20, 2010

Key Late-Breaking Trials to be Presented at TCT 2010


August 19, 2010 – The Cardiovascular Research Foundation recently announced the late-breaking trials and first report investigations being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. Findings from these clinical trials are expected to significantly impact interventional cardiology practices and patient care. TCT 2010 will take place Sept. 21-25 in Washington, D.C.

The studies selected will shed new light on the effectiveness of minimally invasive techniques, pharmaceuticals, technologies and devices that show potential to treat or prevent heart disease, one of the leading causes of death globally.

Late-breaking clinical trials and first report investigations will be highlighted during press conferences scheduled for Thursday, Sept. 23, Friday, Sept. 24, and Saturday, Sept. 25.

THURSDAY, SEPT. 23

Late-Breaking Trials

? PARTNER: A Prospective Randomized Trial of Transcatheter Aortic Valve Implantation Compared to Standard Therapy in Patients with Inoperable Aortic Stenosis

? SPIRIT IV: Two-Year Results from a Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease

? COMPARE: Two-Year Results from a Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease

First Report Investigations

– LANCELOT ACS: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Reversible PAR-1 Thrombin Receptor Antagonist in Patients with Acute Coronary Syndromes

– LEVANT I: A Prospective Randomized Trial of a Paclitaxel-Eluting Balloon Compared to a Non-Drug-Eluting Balloon With and Without Stenting in Patients with Diseased Femoropopliteal Arteries

– PERFECT STENT: A Prospective Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients Treated with Endothelial Progenitor Cell Capturing Stents for De Novo Coronary Artery Disease

FRIDAY, SEPT. 24

Late-Breaking Trials

? ZILVER PTX: A Prospective Randomized Trial of a Paclitaxel-Eluting Stent Compared to Balloon Angioplasty with Provisional Bare Metal Stenting in Patients with Superficial Femoral Artery Disease

– SORT OUT 4: A Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease

– ISAR-TEST-4: Two-Year Clinical and Angiographic Outcomes from a Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease

First Report Investigations

– DES-BTK: A Prospective, Double-Blind, Randomized Trial of Polymer-Free Sirolimus-Eluting Stents Compared to Bare Metal Stents in Patients with Infrapopliteal Disease

– TORPEDO: A Prospective Randomized Trial of Percutaneous Endovenous Intervention Compared to Anticoagulation Alone in Patients with Deep Venous Thrombosis

– BLAST: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Monocyte-Depleting Agent After Bare Metal Stents in Patients with Coronary Artery Disease

SATURDAY, SEPT. 25

Late-Breaking Trials
– ISAR-TEST-5: A Prospective Randomized Trial of Polymer-Free Sirolimus/Probucol-Eluting Stents Compared to Zotarolimus-Eluting Stents in Patients with Coronary Artery Disease

– HORIZONS-AMI: Three-Year Follow-up from a Prospective Randomized Trial of Antithrombin Strategies and Drug-Eluting Stents in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty

– CRISTAL: A Prospective Randomized Trial of Sirolimus-Eluting Stents Compared to Balloon Angioplasty for Restenosis of Drug-Eluting Coronary Stents

First Report Investigations

– BIOFREEDOM: A Prospective Randomized Trial of Polymer-Free Biolimus A9-Eluting Stents and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease

– AVIO: A Prospective Randomized Trial of Intravascular Ultrasound-Guided Compared to Angiography-Guided Stent Implantation in Complex Coronary Lesions

– EXCELLENT: A Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease

To view the program update, visit:
http://www.tctconference.com/pdf/2010program-update.pdf

Receive updates on Twitter: http://twitter.com/TCTConference

View related video content on YouTube:
http://www.youtube.com/user/TCTConference


Related Content

News | Balloon Catheter

June 13, 2024 — The U.S. Food and Drug Administration (FDA) announced that Teleflex, and their subsidiary Arrow ...

Home June 13, 2024
Home
News | Balloon Catheter

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling ...

Home April 04, 2024
Home
News | Balloon Catheter

January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for ...

Home January 18, 2024
Home
News | Balloon Catheter
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional ...
Home February 25, 2022
Home
News | Balloon Catheter

February 15, 2022 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices ...

Home February 15, 2022
Home
News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
Feature | Balloon Catheter

February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...

Home February 17, 2021
Home
News | Balloon Catheter

June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...

Home June 04, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
Subscribe Now